Abstract
Background and objectives COVID-19 can either cause death or go unnoticed but antibodies will remain protecting us of SARS-CoV-2 reinfection for an uncertain time and to an uncertain extent. Our aim was to describe seroprevalence evolution from summer 2019 to autumn 2020 in Spain and to describe its relationship with age, blood group and haematological parameters.
Materials and methods Sera and plasma from historical donation archives excluding convalescent were randomized and a total of 12,313 donations tested by a Chemiluminiscent analysis for anti SARS-CoV-2 N protein total immunoglobulins. Blood donors were 60.9% males, average age 46+/-13. Sex, age, blood group, blood cell counts and percentages and immunoglobulin concentrations were extracted from electronic recordings.
Results A seroprevalence of 6.7% in blood donors was found by the end of the first wave. No differences by sex, age or blood group were found regarding antibodies. Leukocyte count (p=0.026), haematocrit (p<0.001) and haemoglobin (p<0.001) were lower in positive donations than in negative ones. Sex differences were present in neutrophils, leukocytes, haemoglobin and haematocrit as related to SARS-CoV-2 antibodies.
Conclusions Seroprevalence due to asymptomatic cases would resemble that of global population. Sex and age would not affect COVID-19 susceptibility but its severity. Gender differences related to COVID-19 in leukocytes, haemoglobin and haematocrit would be present in asymptomatic individuals. Further studies are needed to confirm these gender differences as they can help better understand the immune response to COVID-19, its pathogenesis and prognosis.
Competing Interest Statement
This work has been carried out provided free equipment and test reagents from Roche Diagnostics International Ltd. M Carmen Martin spoke about this issue in a sponsored symposium of Roche Diagnostics International Ltd.
Funding Statement
This work has been carried out provided free equipment and test reagents from Roche Diagnostics International Ltd.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was conducted according with national regulations, institutional policies and in the tenets of the Helsinki Declaration. This study was approved, with the Valladolid Health Area Drug Research Ethics Committee acting as the main committee, in a meeting held on June 11th, 2020 with the reference number BIO-2020-93
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Baseline characteristics and data fron the original population added
Data Availability
Data collected for the study, including fully anonymized participant data, are available to others. Data available include fully anonymized participant data and data dictionary. Related documents are available from the date of publications henceforth: study protocol, statistical analysis, and approval of Ethical Board. These documents are available from the date of publications henceforth at email address cmartinalo@saludcastillayleon.es. Data would be shared after approval of proposals by the Valladolid Este Ethical Committee.
Abbreviations
- (IgG)
- Immunoglobulin G
- (IgA)
- immunoglobulin A
- (IgM)
- immunoglobulin M
- (PCR)
- polymerase chain reaction
- (SD)
- standard deviation
- (IQR)
- interquartile range
- (WBC)
- White blood cells
- (Hb)
- haemoglobin
- (HCT)
- haematocrit
